Azithromycin vs. Doxycycline for Hospitalized Pneumonia Patients
This study is comparing two common antibiotics, Azithromycin and Doxycycline, in adult patients hospitalized with community-acquired pneumonia (CAP). All participants will also receive another antibiotic called a beta-lactam. Researchers want to see which antibiotic, Azithromycin or Doxycycline, is more effective and safer. You might be able to join if you are an adult (over 18) admitted to the hospital with CAP and are already receiving a beta-lactam antibiotic along with either Azithromycin or Doxycycline. The main goal is to see how many days you are free from the hospital within 28 days. The study status is currently unclear.
- Study design
- This interventional study plans to enroll 1120 adult participants. Participants will receive either Doxycycline or Azithromycin in combination with a beta-lactam.
- What's involved
- Participants will receive either Doxycycline or Azithromycin, orally or intravenously, for 5-7 days within 12 hours of hospital admission.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, hospital-free days, is measured at 28 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
At a glance
Conditions
Where it's being run
5 sites across 4 statesStudy leadership
- Yewande Odeyemi · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Hospital-free days28 days
Number of days subject remained out of hospital